Advanced search
Publication Cover
OncoImmunology Volume 1, 2012 - Issue 7
Submit an article Journal homepage
1,880
Views
55
CrossRef citations to date
0
Altmetric
Original Research

Expression of MHC Class I on breast cancer cells correlates inversely with HER2 expression

Masayuki Inoue First Department of Surgery; University of Yamanashi; Yamanashi, Japan
,
Kousaku Mimura First Department of Surgery; University of Yamanashi; Yamanashi, Japan; Department of Surgery; Yong Loo Lin School of Medicine; National University of Singapore; NUHS Tower Block; Singapore, Singapore
,
Shinichiro Izawa First Department of Surgery; University of Yamanashi; Yamanashi, Japan
,
Kensuke Shiraishi First Department of Surgery; University of Yamanashi; Yamanashi, Japan
,
Ayako Inoue First Department of Surgery; University of Yamanashi; Yamanashi, Japan
,
Shugo Shiba First Department of Surgery; University of Yamanashi; Yamanashi, Japan
,
Mitsuaki Watanabe First Department of Surgery; University of Yamanashi; Yamanashi, Japan
,
Takanori Maruyama First Department of Surgery; University of Yamanashi; Yamanashi, Japan
,
Yoshihiko Kawaguchi First Department of Surgery; University of Yamanashi; Yamanashi, Japan
,
Shingo Inoue First Department of Surgery; University of Yamanashi; Yamanashi, Japan
,
Tomonori Kawasaki Department of Pathology; University of Yamanashi; Yamanashi, Japan
,
Aniruddha Choudhury Centre for Immune and Targeted Therapy; Greenslopes Private Hospital; University of Queensland; Greenslopes, Australia
,
Ryohei Katoh Department of Pathology; University of Yamanashi; Yamanashi, Japan
,
Hideki Fujii First Department of Surgery; University of Yamanashi; Yamanashi, Japan
,
Rolf Kiessling Department of Oncology and Pathology; Immune and Gene Therapy Laboratory; Cancer Center Karolinska; R8:01; Karolinska Hospital; Stockholm, Sweden
&
Koji Kono First Department of Surgery; University of Yamanashi; Yamanashi, Japan; Department of Surgery; Yong Loo Lin School of Medicine; National University of Singapore; NUHS Tower Block; Singapore, Singapore; Cancer Science Institute of Singapore; National University of Singapore; Singapore, SingaporeCorrespondence[email protected]
 show all
Pages 1104-1110 | Received 01 Mar 2012, Accepted 08 Jun 2012, Published online: 01 Oct 2012

Citations (55)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Silvio Bandini, Marco Macagno, Albana Hysi, Stefania Lanzardo, Laura Conti, Amanda Bello, Federica Riccardo, Roberto Ruiu, Irene Fiore Merighi, Guido Forni, Manuela Iezzi, Elena Quaglino & Federica Cavallo. (2016) The non-inflammatory role of C1q during Her2/neu-driven mammary carcinogenesis. OncoImmunology 5:12.
Read now
Bharat K. R. Chaganty, Yang Lu, Songbo Qiu, Srinivas S. Somanchi, Dean A. Lee & Zhen Fan. (2016) Trastuzumab upregulates expression of HLA-ABC and T cell costimulatory molecules through engagement of natural killer cells and stimulation of IFNγ secretion. OncoImmunology 5:4.
Read now
Fernando Aranda, Erika Vacchelli, Florine Obrist, Alexander Eggermont, Jérôme Galon, Wolf Hervé Fridman, Isabelle Cremer, Eric Tartour, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2014) Trial Watch. OncoImmunology 3:5.
Read now
Silvio Bandini, Claudia Curcio, Marco Macagno, Elena Quaglino, Maddalena Arigoni, Stefania Lanzardo, Albana Hysi, Giuseppina Barutello, Lorena Consolino, Dario Livio Longo, Piero Musiani, Guido Forni, Manuela Iezzi & Federica Cavallo. (2013) Early onset and enhanced growth of autochthonous mammary carcinomas in C3-deficient Her2/neu transgenic mice. OncoImmunology 2:9.
Read now

Articles from other publishers (51)

Galaxia M. Rodriguez, Edward Yakubovich & Barbara C. Vanderhyden. (2023) Unveiling the Immunogenicity of Ovarian Tumors as the Crucial Catalyst for Therapeutic Success. Cancers 15:23, pages 5694.
Crossref
Megan G. Matherne, Emily S. Phillips, Samuel J. Embrey, Caitlin M. Burke & Heather L. Machado. (2023) Emerging functions of C/EBPβ in breast cancer. Frontiers in Oncology 13.
Crossref
Zuzana Tatarova, Dylan C. Blumberg, James E. Korkola, Laura M. Heiser, John L. Muschler, Pepper J. Schedin, Sebastian W. Ahn, Gordon B. Mills, Lisa M. Coussens, Oliver Jonas & Joe W. Gray. (2022) A multiplex implantable microdevice assay identifies synergistic combinations of cancer immunotherapies and conventional drugs. Nature Biotechnology 40:12, pages 1823-1833.
Crossref
Davide Massa, Anna Tosi, Antonio Rosato, Valentina Guarneri & Maria Vittoria Dieci. (2022) Multiplexed In Situ Spatial Protein Profiling in the Pursuit of Precision Immuno-Oncology for Patients with Breast Cancer. Cancers 14:19, pages 4885.
Crossref
Fiorella Rossi, Nathaniel Fredericks, Andrew Snowden, Michael J. Allegrezza & Uriel Y. Moreno-Nieves. (2022) Next Generation Natural Killer Cells for Cancer Immunotherapy. Frontiers in Immunology 13.
Crossref
Hanxiao Li, P. Anton van der Merwe & Shivan Sivakumar. (2022) Biomarkers of response to PD-1 pathway blockade. British Journal of Cancer 126:12, pages 1663-1675.
Crossref
Ananthan Sadagopan, Theodoros Michelakos, Gabriella Boyiadzis, Cristina Ferrone & Soldano Ferrone. (2022) Human Leukocyte Antigen Class I Antigen-Processing Machinery Upregulation by Anticancer Therapies in the Era of Checkpoint Inhibitors. JAMA Oncology 8:3, pages 462.
Crossref
Brandie C. Taylor & Justin M. Balko. (2022) Mechanisms of MHC-I Downregulation and Role in Immunotherapy Response. Frontiers in Immunology 13.
Crossref
Jessica J. Roetman, Minna K. I. Apostolova & Mary Philip. (2022) Viral and cellular oncogenes promote immune evasion. Oncogene 41:7, pages 921-929.
Crossref
Shotaro Nakajima, Kosaku Mimura, Takuro Matsumoto, Aung Kyi Thar Min, Misato Ito, Hiroshi Nakano, Prajwal Neupane, Yasuyuki Kanke, Hirokazu Okayama, Motonobu Saito, Tomoyuki Momma, Yohei Watanabe, Hiroyuki Hanayama, Suguru Hayase, Zenichiro Saze & Koji Kono. (2021) The effects of T-DXd on the expression of HLA class I and chemokines CXCL9/10/11 in HER2-overexpressing gastric cancer cells. Scientific Reports 11:1.
Crossref
Luke Maggs, Ananthan Sadagopan, Ali Sanjari Moghaddam & Soldano Ferrone. (2021) HLA class I antigen processing machinery defects in antitumor immunity and immunotherapy. Trends in Cancer 7:12, pages 1089-1101.
Crossref
Leisha A Emens, Sylvia Adams, Ashley Cimino-Mathews, Mary L Disis, Margaret E Gatti-Mays, Alice Y Ho, Kevin Kalinsky, Heather L McArthur, Elizabeth A Mittendorf, Rita Nanda, David B Page, Hope S Rugo, Krista M Rubin, Hatem Soliman, Patricia A Spears, Sara M Tolaney & Jennifer K Litton. (2021) Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer. Journal for ImmunoTherapy of Cancer 9:8, pages e002597.
Crossref
Miganoosh Simonian, Mozhan Haji Ghaffari & Babak Negahdari. (2021) Immunotherapy for Breast Cancer Treatment. Iranian Biomedical Journal 25:3, pages 140-156.
Crossref
Anna C. Dusenbery, Joseph L. Maniaci, Natalie D. Hillerson, Erik A. Dill, Timothy N. Bullock & Anne M. Mills. (2021) MHC Class I Loss in Triple-negative Breast Cancer. American Journal of Surgical Pathology 45:5, pages 701-707.
Crossref
Guoyu Mu, Hong Ji, Hui He & Hongjiang Wang. (2020) Immune-related gene data-based molecular subtyping related to the prognosis of breast cancer patients. Breast Cancer 28:2, pages 513-526.
Crossref
Sayuri Yoshihama, Steven X. Cho, Jason Yeung, Xuedong Pan, Gregory Lizee, Kranti Konganti, Valen E. Johnson & Koichi S. Kobayashi. (2021) NLRC5/CITA expression correlates with efficient response to checkpoint blockade immunotherapy. Scientific Reports 11:1.
Crossref
Annelisa M. Cornel, Iris L. Mimpen & Stefan Nierkens. (2020) MHC Class I Downregulation in Cancer: Underlying Mechanisms and Potential Targets for Cancer Immunotherapy. Cancers 12:7, pages 1760.
Crossref
Evren Atlihan-Gundogdu, Derya Ilem-Ozdemir, Meliha Ekinci, Emre Ozgenc, Emine Selin Demir, Bárbara Sánchez-Dengra & Isabel González-Alvárez. (2020) Recent developments in cancer therapy and diagnosis. Journal of Pharmaceutical Investigation 50:4, pages 349-361.
Crossref
Julia Y. Tsang, Chun-Sing Ho, Yun-Bi Ni, Yan Shao, Ivan K. Poon, Siu-Ki Chan, Sai-Yin Cheung, Ka-Ho Shea, Monalyn Marabi & Gary M. Tse. (2020) Co-expression of HLA-I loci improved prognostication in HER2+ breast cancers. Cancer Immunology, Immunotherapy 69:5, pages 799-811.
Crossref
Jing Zhao & Jian Huang. (2020) Breast cancer immunology and immunotherapy: targeting the programmed cell death protein-1/programmed cell death protein ligand-1. Chinese Medical Journal 133:7, pages 853-862.
Crossref
Barbara Seliger & Soldano Ferrone. 2020. Biomarkers for Immunotherapy of Cancer. Biomarkers for Immunotherapy of Cancer 325 350 .
Sanjay Chandrasekaran, Maiko Sasaki, Christopher D. Scharer, Haydn T. Kissick, Dillon G. Patterson, Kelly R. Magliocca, John T. Seykora, Bishu Sapkota, David A. Gutman, Lee A. Cooper, Gregory B. Lesinski, Edmund K. Waller, Susan N. Thomas, Sergei V. Kotenko, Jeremy M. Boss, Carlos S. Moreno, Robert A. Swerlick & Brian P. Pollack. (2019) Phosphoinositide 3-Kinase Signaling Can Modulate MHC Class I and II Expression. Molecular Cancer Research 17:12, pages 2395-2409.
Crossref
Ming-Zhen Zhao, Yu Sun, Xiao-Feng Jiang, Li Liu, Li Liu & Li-Xin Sun. (2020) Promotion on NLRC5 upregulating MHC-I expression by IFN-γ in MHC-I–deficient breast cancer cells. Immunologic Research 67:6, pages 497-504.
Crossref
Marilina García-Aranda & Maximino Redondo. (2019) Immunotherapy: A Challenge of Breast Cancer Treatment. Cancers 11:12, pages 1822.
Crossref
Aftab Alam, Nandaraj Taye, Sonal Patel, Milind Thube, Jayati Mullick, Vibhuti Kumar Shah, Richa Pant, Tanaya Roychowdhury, Nilanjan Banerjee, Subhrangsu Chatterjee, Rittwika Bhattacharya, Rini Roy, Ashis Mukhopadhyay, Devraj Mogare & Samit Chattopadhyay. (2019) SMAR1 favors immunosurveillance of cancer cells by modulating calnexin and MHC I expression. Neoplasia 21:10, pages 945-962.
Crossref
M. Messaoudene, T.P. Mourikis, J. Michels, Y. Fu, M. Bonvalet, M. Lacroix-Trikki, B. Routy, A. Fluckiger, S. Rusakiewicz, M.P. Roberti, S. Cotteret, C. Flament, V. Poirier-Colame, N. Jacquelot, F. Ghiringhelli, A. Caignard, A.M.M. Eggermont, G. Kroemer, A. Marabelle, M. Arnedos, C. Vicier, S. Dogan, F. Jaulin, S -J Sammut, W. Cope, C. Caldas, S. Delaloge, N. McGranahan, F. André & L. Zitvogel. (2019) T-cell bispecific antibodies in node-positive breast cancer: novel therapeutic avenue for MHC class I loss variants. Annals of Oncology 30:6, pages 934-944.
Crossref
Cathy Eng, Tae Won Kim, Johanna Bendell, Guillem Argilés, Niall C Tebbutt, Maria Di Bartolomeo, Alfredo Falcone, Marwan Fakih, Mark Kozloff, Neil H Segal, Alberto Sobrero, Yibing Yan, Ilsung Chang, Anne Uyei, Louise Roberts, Fortunato Ciardiello, JB Ahn, J Asselah, S Badarinath, S Baijal, S Begbie, S Berry, JL Canon, RG Carbone, A Cervantes, YJ Cha, K Chang, A Chaudhry, E Chmielowska, SH Cho, D Chu, F Couture, J Cultrera, D Cunningham, E Van Cutsem, PJ Cuyle, J Davies, S Dowden, M Dvorkin, V Ganju, RV Garcia, R Kerr, TY Kim, K King, J Kortmansky, M Kozloff, KO Lam, J Lee, AS Lee, B Lesperance, G Luppi, B Ma, E Maiello, R Mandanas, J Marshall, G Marx, S Mullamitha, M Nechaeva, JO Park, N Pavlakis, CG Ponce, P Potemski, S Raouf, J Reeves, N Segal, S Siena, A Smolin, JO Streb, A Strickland, E Szutowicz-Zielinska, JM Tabernero, B Tan, JS Valera, M Van den Eynde, P Vergauwe, M Vickers, M Womack, M Wroblewska & R Young. (2019) Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. The Lancet Oncology 20:6, pages 849-861.
Crossref
Safikur Rahman, Ayyagari Archana, Arif Tasleem Jan, Durgashree Dutta, Abhishek Shankar, Jihoe Kim & Rinki Minakshi. (2019) Molecular Insights Into the Relationship Between Autoimmune Thyroid Diseases and Breast Cancer: A Critical Perspective on Autoimmunity and ER Stress. Frontiers in Immunology 10.
Crossref
Tung Nguyen Thanh Uong, Kyung-Hwa Lee, Sung-Ja Ahn, Kyung Won Kim, Jung-Joon Min, Hoon Hyun & Mee Sun Yoon. (2018) Real-Time Tracking of Ex Vivo-Expanded Natural Killer Cells Toward Human Triple-Negative Breast Cancers. Frontiers in Immunology 9.
Crossref
Issam Makhoul, Mohammad Atiq, Ahmed Alwbari & Thomas Kieber-Emmons. (2018) Breast Cancer Immunotherapy: An Update. Breast Cancer: Basic and Clinical Research 12, pages 117822341877480.
Crossref
Issam Makhoul. 2018. The Breast. The Breast 315 330.e7 .
Virginia Aragon-Sanabria, Gloria B. Kim & Cheng Dong. 2018. Biomechanics in Oncology. Biomechanics in Oncology 113 138 .
Aura Muntasell, Mariona Cabo, Sonia Servitja, Ignasi Tusquets, María Martínez-García, Ana Rovira, Federico Rojo, Joan Albanell & Miguel López-Botet. (2017) Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy. Frontiers in Immunology 8.
Crossref
Nyanbol Kuol, Lily Stojanovska, Kulmira Nurgali & Vasso Apostolopoulos. (2017) The mechanisms tumor cells utilize to evade the host's immune system. Maturitas 105, pages 8-15.
Crossref
Peter J. Stambrook, John Maher & Farzin Farzaneh. (2017) Cancer Immunotherapy: Whence and Whither. Molecular Cancer Research 15:6, pages 635-650.
Crossref
Fernando Concha-Benavente & Robert L Ferris. (2017) Oncogenic growth factor signaling mediating tumor escape from cellular immunity. Current Opinion in Immunology 45, pages 52-59.
Crossref
Sayuri Yoshihama, Saptha Vijayan, Tabasum Sidiq & Koichi S. Kobayashi. (2017) NLRC5/CITA: A Key Player in Cancer Immune Surveillance. Trends in Cancer 3:1, pages 28-38.
Crossref
Marie de Charette, Aurélien Marabelle & Roch Houot. (2016) Turning tumour cells into antigen presenting cells: The next step to improve cancer immunotherapy?. European Journal of Cancer 68, pages 134-147.
Crossref
Omar Fahmy, Mohd Ghani Khairul-Asri, Arnulf Stenzl & Georgios Gakis. (2016) The current status of checkpoint inhibitors in metastatic bladder cancer. Clinical & Experimental Metastasis 33:7, pages 629-635.
Crossref
Thi Tran, Mariana O. Diniz, Estelle Dransart, Alain Gey, Nathalie Merillon, Yu Chun Lone, Sylvie Godefroy, Craig Sibley, Luis CS Ferreira, Jacques Medioni, Stephane Oudard, Ludger Johannes & Eric Tartour. (2016) A Therapeutic Her2/neu Vaccine Targeting Dendritic Cells Preferentially Inhibits the Growth of Low Her2/neu–Expressing Tumor in HLA-A2 Transgenic Mice. Clinical Cancer Research 22:16, pages 4133-4144.
Crossref
Sayuri YoshihamaJason RoszikIsaac DownsTorsten B. MeissnerSaptha VijayanBjoern ChapuyTabasum SidiqMargaret A. ShippGregory A. Lizee & Koichi S. Kobayashi. (2016) NLRC5/MHC class I transactivator is a target for immune evasion in cancer. Proceedings of the National Academy of Sciences 113:21, pages 5999-6004.
Crossref
Guido Kroemer, Laura Senovilla, Lorenzo Galluzzi, Fabrice André & Laurence Zitvogel. (2015) Natural and therapy-induced immunosurveillance in breast cancer. Nature Medicine 21:10, pages 1128-1138.
Crossref
Hee Jin Lee, Joo Young Kim, In Ah Park, In Hye Song, Jong Han Yu, Jin-Hee Ahn & Gyungyub Gong. (2015) Prognostic Significance of Tumor-Infiltrating Lymphocytes and the Tertiary Lymphoid Structures in HER2-Positive Breast Cancer Treated With Adjuvant Trastuzumab. American Journal of Clinical Pathology 144:2, pages 278-288.
Crossref
Kemal Beksac, Meral Beksac, Klara Dalva, Ergun Karaagaoglu & M. Bulent Tirnaksiz. (2015) Impact of “Killer Immunoglobulin-Like Receptor /Ligand” Genotypes on Outcome following Surgery among Patients with Colorectal Cancer: Activating KIRs Are Associated with Long-Term Disease Free Survival. PLOS ONE 10:7, pages e0132526.
Crossref
Sherille D. Bradley, Zeming Chen, Brenda Melendez, Amjad Talukder, Jahan S. Khalili, Tania Rodriguez-Cruz, Shujuan Liu, Mayra Whittington, Wanleng Deng, Fenge Li, Chantale Bernatchez, Laszlo G. Radvanyi, Michael A. Davies, Patrick Hwu & Gregory Lizée. (2015) BRAFV600E Co-opts a Conserved MHC Class I Internalization Pathway to Diminish Antigen Presentation and CD8+ T-cell Recognition of Melanoma. Cancer Immunology Research 3:6, pages 602-609.
Crossref
Jashodeep Datta, Shuwen Xu, Cinthia Rosemblit, Jenessa B. Smith, Jessica A. Cintolo, Daniel J. PowellJrJr & Brian J. Czerniecki. (2015) CD4+ T-Helper Type 1 Cytokines and Trastuzumab Facilitate CD8+ T-cell Targeting of HER2/ neu –Expressing Cancers . Cancer Immunology Research 3:5, pages 455-463.
Crossref
Kellie B. Haworth, Jennifer L. Leddon, Chun‐Yu Chen, Edwin M. Horwitz, Crystal L. Mackall & Timothy P. Cripe. (2014) Going back to class I: MHC and immunotherapies for childhood cancer. Pediatric Blood & Cancer 62:4, pages 571-576.
Crossref
Stefanie Raab, Julia Steinbacher, Benjamin J. Schmiedel, Philaretos C. Kousis, Alexander Steinle, Gundram Jung, Ludger Grosse-Hovest & Helmut R. Salih. (2014) Fc-Optimized NKG2D–Fc Constructs Induce NK Cell Antibody-Dependent Cellular Cytotoxicity against Breast Cancer Cells Independently of HER2/neu Expression Status. The Journal of Immunology 193:8, pages 4261-4272.
Crossref
Laura Conti, Roberto Ruiu, Giuseppina Barutello, Marco Macagno, Silvio Bandini, Federica Cavallo & Stefania Lanzardo. (2014) Microenvironment, Oncoantigens, and Antitumor Vaccination: Lessons Learned from BALB-neuT Mice. BioMed Research International 2014, pages 1-16.
Crossref
Barbara Seliger & Rolf Kiessling. (2013) The two sides of HER2/neu: immune escape versus surveillance. Trends in Molecular Medicine 19:11, pages 677-684.
Crossref
Yuexin Pan, Jerzy Trojan, Yajun Guo & Donald D. Anthony. (2013) Rescue of MHC-1 Antigen Processing Machinery by Down-Regulation in Expression of IGF-1 in Human Glioblastoma Cells. PLoS ONE 8:3, pages e58428.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.